Participants should read the activity information, review the activity in its entirety, and complete the online posttest and evaluation. Upon completing this activity as designed and achieving a passing score on the posttest, you will be directed to a Web page that will provide you information on how to receive your certificate of credit via e-mail or print it out. The online posttest and evaluation can be accessed at: https://tinyurl.com/AsthmaChest18.
Inquiries may be directed to Global Academy for Medical Education at firstname.lastname@example.org or (973) 290-8225 or Postgraduate Institute for Medicine at (720) 895-5357.
Mario Castro, MD, MPH
Nicola A. Hanania, MD, MS, FCCP
F. Eun-Hyung Lee, MD
Merin Kuruvilla, MD
CME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Chest Physicians (CHEST) and Global Academy for Medical Education. The American College of Chest Physicians is accredited by the ACCME to provide continuing education for physicians.
The American College of Chest Physicians designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education.
Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Continuing Nursing Education: The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 1.0 of pharmacotherapy credit for Advanced Practice Nurses.
Maintenance of Certification (MOC) Statement
Successful completion of this CME activity enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Upon successful completion of this course, CHEST will submit your completion data to ABIM via ACCME's Program and Activity Reporting System (PARS) for MOC points. Please allow 30 business days for your points to be reflected on your ABIM record.
At the conclusion of this program, participants should be better able to:
- List the steps in the assessment of a patient with poorly controlled asthma
- Explain the use of advanced therapies, including biologics and bronchial thermoplasty
- Describe recent research on non–type 2 asthma and appropriate treatment strategies for it
- Explain how to use decision aids and other tools with patients to guide them in shared decision making
Statement of Need
The advent of targeted therapies and biomarkers in recent years has the potential to improve the care of severe asthma, but it also increases the complexity of its management. New data on biomarkers and asthma endotypes can help physicians choose among treatment options for particular groups of patients. New tools can help busy physicians share decision making with their patients. Clinicians are challenged to remain current with recommendations for applying the latest advances to clinical care. This supplement summarizes selected presentations about the most recent clinical and pathophysiological evidence in severe asthma from the annual meeting of the American College of Chest Physicians.
Individuals in a position to control the content of this educational activity are required to disclose: 1) the existence of any relevant financial relationship with any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ACCME-defined commercial interests related to the content of this CME activity:
Mario Castro, MD, MPH, Consultant: 4D Pharma, Aviragen, Boston Scientific, Genentech, Mallinckrodt, Nuvaira, Sanofi-Aventis, Teva, Therabron, Theravance, and VIDA. Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, and Sanofi-Aventis. Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Boston Scientific, Genentech, and Teva. Royalty: Elsevier.
Nicola A. Hanania, MD, MS, FCCP, Consultant: AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi Genzyme. Grant/Research Support: AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline.
F. Eun-Hyung Lee, MD, Consultant: AstraZeneca. Receipt of Intellectual Property Rights/Patent Holder: MicroBplex, Inc.
Merin Kuruvilla, MD, has nothing to disclose.
American College of Chest Physicians (CHEST) staff have nothing to disclose.
The Postgraduate Institute for Medicine planners and managers have nothing to disclose.
Global Academy for Medical Education planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Copyright © 2019 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC and Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.